143 related articles for article (PubMed ID: 15811552)
21. Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions.
Therrien C; Dodig D; Karpati G; Sinnreich M
J Neurol Sci; 2006 Dec; 250(1-2):71-8. PubMed ID: 16996541
[TBL] [Abstract][Full Text] [Related]
22. Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding.
Wenzel K; Carl M; Perrot A; Zabojszcza J; Assadi M; Ebeling M; Geier C; Robinson PN; Kress W; Osterziel KJ; Spuler S
Hum Mutat; 2006 Jun; 27(6):599-600. PubMed ID: 16705711
[TBL] [Abstract][Full Text] [Related]
23. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies.
Cagliani R; Magri F; Toscano A; Merlini L; Fortunato F; Lamperti C; Rodolico C; Prelle A; Sironi M; Aguennouz M; Ciscato P; Uncini A; Moggio M; Bresolin N; Comi GP
Hum Mutat; 2005 Sep; 26(3):283. PubMed ID: 16100712
[TBL] [Abstract][Full Text] [Related]
24. Symptomatic dysferlin gene mutation carriers: characterization of two cases.
Illa I; De Luna N; Domínguez-Perles R; Rojas-García R; Paradas C; Palmer J; Márquez C; Gallano P; Gallardo E
Neurology; 2007 Apr; 68(16):1284-9. PubMed ID: 17287450
[TBL] [Abstract][Full Text] [Related]
25. Continuous administration of poloxamer 188 reduces overload-induced muscular atrophy in dysferlin-deficient SJL mice.
Suzuki N; Akiyama T; Takahashi T; Komuro H; Warita H; Tateyama M; Itoyama Y; Aoki M
Neurosci Res; 2012 Feb; 72(2):181-6. PubMed ID: 22044584
[TBL] [Abstract][Full Text] [Related]
26. Dysferlin and the plasma membrane repair in muscular dystrophy.
Bansal D; Campbell KP
Trends Cell Biol; 2004 Apr; 14(4):206-13. PubMed ID: 15066638
[TBL] [Abstract][Full Text] [Related]
27. Muscle inflammation, autoimmune Addison's disease and sarcoidosis in a patient with dysferlin deficiency.
Selva-O'Callaghan A; Labrador-Horrillo M; Gallardo E; Herruzo A; Grau-Junyent JM; Vilardell-Tarres M
Neuromuscul Disord; 2006 Mar; 16(3):208-9. PubMed ID: 16483775
[TBL] [Abstract][Full Text] [Related]
28. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.
Nagaraju K; Rawat R; Veszelovszky E; Thapliyal R; Kesari A; Sparks S; Raben N; Plotz P; Hoffman EP
Am J Pathol; 2008 Mar; 172(3):774-85. PubMed ID: 18276788
[TBL] [Abstract][Full Text] [Related]
29. Anti-TNF therapy using etanercept suppresses degenerative and inflammatory changes in skeletal muscle of older SJL/J mice.
Nemoto H; Konno S; Sugimoto H; Nakazora H; Nomoto N; Murata M; Kitazono H; Fujioka T
Exp Mol Pathol; 2011 Jun; 90(3):264-70. PubMed ID: 21324312
[TBL] [Abstract][Full Text] [Related]
30. Challenges for the genetic screening in dysferlin deficiency--report of an instructive case and review of the literature.
Gal A; Siska E; Nagy Z; Karpati G; Molnar MJ
Clin Neuropathol; 2008; 27(5):289-94. PubMed ID: 18808059
[TBL] [Abstract][Full Text] [Related]
31. Proteomic investigation of the molecular pathophysiology of dysferlinopathy.
De Palma S; Morandi L; Mariani E; Begum S; Cerretelli P; Wait R; Gelfi C
Proteomics; 2006 Jan; 6(1):379-85. PubMed ID: 16302276
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice.
Kostek CA; Dominov JA; Miller JB
Am J Pathol; 2002 Mar; 160(3):833-9. PubMed ID: 11891182
[TBL] [Abstract][Full Text] [Related]
33. A case of dysferlinopathy presenting choreic movements.
Takahashi T; Aoki M; Imai T; Yoshioka M; Konno H; Higano S; Onodera Y; Saito H; Kimura I; Itoyama Y
Mov Disord; 2006 Sep; 21(9):1513-5. PubMed ID: 16817213
[TBL] [Abstract][Full Text] [Related]
34. Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset.
Kesari A; Fukuda M; Knoblach S; Bashir R; Nader GA; Rao D; Nagaraju K; Hoffman EP
Am J Pathol; 2008 Nov; 173(5):1476-87. PubMed ID: 18832576
[TBL] [Abstract][Full Text] [Related]
35. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network.
Schiekofer S; Galasso G; Sato K; Kraus BJ; Walsh K
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1603-9. PubMed ID: 15920034
[TBL] [Abstract][Full Text] [Related]
36. Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limb-girdle muscular dystrophy 2B.
Chase TH; Cox GA; Burzenski L; Foreman O; Shultz LD
Am J Pathol; 2009 Dec; 175(6):2299-308. PubMed ID: 19875504
[TBL] [Abstract][Full Text] [Related]
37. Dysferlin and animal models for dysferlinopathy.
Kobayashi K; Izawa T; Kuwamura M; Yamate J
J Toxicol Pathol; 2012 Jun; 25(2):135-47. PubMed ID: 22907980
[TBL] [Abstract][Full Text] [Related]
38. [Dysferlin expression in limb-girdle muscular dystrophy and Miyoshi myopathy: analysis of 45 cases].
Ren SC; Yan CZ; Li MX; Liu SP; Wu JL; Zhao YY; Li W; Li DN
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1486-90. PubMed ID: 17785089
[TBL] [Abstract][Full Text] [Related]
39. Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation.
Vafiadaki E; Reis A; Keers S; Harrison R; Anderson LV; Raffelsberger T; Ivanova S; Hoger H; Bittner RE; Bushby K; Bashir R
Neuroreport; 2001 Mar; 12(3):625-9. PubMed ID: 11234777
[TBL] [Abstract][Full Text] [Related]
40. Dysferlin expression in tubular aggregates: their possible relationship to endoplasmic reticulum stress.
Ikezoe K; Furuya H; Ohyagi Y; Osoegawa M; Nishino I; Nonaka I; Kira J
Acta Neuropathol; 2003 Jun; 105(6):603-9. PubMed ID: 12664320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
